PDS Biotechnology Corp Total Assets
PDS Biotechnology Corp total assets. Based on the latest financial reports, PDS Biotechnology Corp (PDSB) holds total assets worth $8.81 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is PDS Biotechnology Corp worth for the company's overall valuation and market capitalisation.
Total Assets of PDS Biotechnology Corp (2012–2025)
Total assets of PDS Biotechnology Corp from 2012 to 2025. This chart illustrates how PDS Biotechnology Corp's total assets have evolved over time, based on quarterly financial data. See PDS Biotechnology Corp share price for real-time trading data and today's change.
PDS Biotechnology Corp - Asset Composition Analysis
PDS Biotechnology Corp Total Assets Breakdown (December 2025)
PDS Biotechnology Corp total assets breakdown as of December 2025. PDS Biotechnology Corp's total assets of $8.81 Million consist of 92.7% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 87.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PDS Biotechnology Corp working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PDS Biotechnology Corp's current assets represent 92.7% of total assets in 2025, an increase from 90.0% in 2012.
- Cash Position: Cash and equivalents constituted 87.6% of total assets in 2025, up from 86.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
PDS Biotechnology Corp Competitors by Total Assets
Key competitors of PDS Biotechnology Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
PDS Biotechnology Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.57 | 2.92 | 19.94 |
| Quick Ratio | 0.57 | 2.92 | 19.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.33 Million | $22.12 Million | $67.76 Million |
PDS Biotechnology Corp - Advanced Valuation Insights
This section examines the relationship between PDS Biotechnology Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.47 |
| Latest Market Cap to Assets Ratio | 2.42 |
| Asset Growth Rate (YoY) | -32.8% |
| Total Assets | $30.49 Million |
| Market Capitalization | $73.92 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values PDS Biotechnology Corp's assets at a significant premium (2.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: PDS Biotechnology Corp's assets decreased by 32.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PDS Biotechnology Corp (2012–2025)
The table below shows the annual total assets of PDS Biotechnology Corp from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $30.49 Million | -32.77% |
| 2024-12-31 | $45.36 Million | -23.63% |
| 2023-12-31 | $59.39 Million | -22.88% |
| 2022-12-31 | $77.01 Million | +14.60% |
| 2021-12-31 | $67.20 Million | +117.54% |
| 2020-12-31 | $30.89 Million | +113.17% |
| 2019-12-31 | $14.49 Million | -59.99% |
| 2018-12-31 | $36.22 Million | -60.89% |
| 2017-12-31 | $92.62 Million | -16.49% |
| 2016-12-31 | $110.91 Million | -17.29% |
| 2015-12-31 | $134.09 Million | +686.62% |
| 2014-12-31 | $17.05 Million | +95.18% |
| 2013-12-31 | $8.73 Million | +5233.42% |
| 2012-12-31 | $163.76K | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more